Remdesivir and Obeldesivir Maintain Effectiveness Against Evolving COVID-19 Variants
As SARS-CoV-2 continues to mutate, antiviral treatments must demonstrate ongoing efficacy. Recent research confirms that remdesivir and its oral prodrug, obeldesivir, retain potent antiviral activity against current Omicron subvariants, offering continued therapeutic options for COVID-19.
Continued Potency Against Omicron Subvariants
A study published in January 2026 in Open Forum Infectious Diseases, building on previous research in Viruses from January 25, 2025, assessed the effectiveness of remdesivir and obeldesivir against Omicron subvariants circulating from September 2023 through June 2025, including XBB.2 and BA.2.86. The findings, conducted by researchers at Gilead Sciences, Inc., and Johns Hopkins Bloomberg School of Public Health, are reassuring as the virus evolves.
How Remdesivir and Obeldesivir Operate
Remdesivir, an intravenous nucleotide analog prodrug, is approved for treating COVID-19 in both hospitalized and non-hospitalized patients. Obeldesivir is an oral formulation that metabolizes into the same active form as remdesivir, potentially offering a more convenient administration route. Both drugs target the viral RNA-dependent RNA polymerase, Nsp12, which is essential for viral replication.
Research Methodology
The research team evaluated antiviral activity against recent Omicron variants using clinical isolates and a replicon system. This system introduces variant-defining substitutions into a replicating RNA molecule, allowing scientists to isolate and study the impact of specific mutations on drug susceptibility.
Implications for COVID-19 Treatment
The data indicate that remdesivir and obeldesivir maintain their antiviral potency against newer Omicron subvariants. Even as specific potency details weren’t provided, the consistent activity suggests the virus hasn’t developed significant resistance to these medications. This is particularly important given the ongoing emergence of fresh variants with potentially altered characteristics.
Real-World Evidence Supports Remdesivir’s Effectiveness
A retrospective observational study, ReEs-COVID19, provided real-world evidence of remdesivir’s effectiveness and safety across two periods: pre-Omicron and Omicron. Further research indicates that the benefits of remdesivir treatment during the late Omicron period (January 2023 through February 2024) were comparable to those observed during the early Omicron period (December 2021 through January 2023).